Objective: To investigate the efficacy and safety of transurethral seminal vesiculoscopy in the diagnosis and treatment of intractable seminal vesiculitis. Methods: This prospective observational study enrolled patients with intractable seminal vesiculitis. The transurethral seminal vesiculoscope was inserted into the bilateral ejaculatory ducts and seminal vesicles, via the urethra. The ejaculatory ducts and seminal vesicles were visualized to confirm the diagnosis of seminal vesiculitis and to determine the cause of the disease. The seminal vesicles were washed repeatedly using 0.90% (w/v) sodium chloride before a 0.50% (w/v) levofloxacin solution was injected into the seminal vesicles.
Introduction
Seminal vesiculitis is frequently encountered by urologists and andrologists. Haematospermia and lower abdominal (or perineal) pain and discomfort are the most common clinical manifestations. A variety of pathological causes can result in haematospermia. 1 Seminal vesiculitis is one of the most common causes, especially in patients under 40 years old. 1, 2 Although seminal vesiculitis is a benign and self-limiting disease, recurrent episodes lead to anxiety, fear, erectile dysfunction and even male infertility. 2 Lesions in the male urogenital tract (urethra, prostate and seminal vesicle) can cause haematospermia, and lower abdominal or perineal pain and discomfort. Systemic diseases, such as serious hypertension and bleeding tendency, can occasionally lead to haematospermia. In addition, the anatomical position of the seminal vesicles is complex and concealed. For these reasons, the diagnosis of seminal vesiculitis relies mainly on the typical clinical manifestations, which means that sometimes it is difficult to distinguish seminal vesiculitis from prostatitis. Transrectal ultrasonography (TRUS) and pelvic magnetic resonance imaging (MRI) are helpful for the diagnosis by excluding congenital abnormalities or tumours in the urogenital tract. [3] [4] [5] [6] The main treatments for seminal vesiculitis are systemic antibiotics and local physiotherapy. However, long-term medication use and a high recurrence rate are the major problems associated with intractable seminal vesiculitis. Transperineal puncture for direct drug injection into the seminal vesicles may cause damage to the rectum or bladder, bleeding, and infection: 7 a more effective and safer treatment method is needed for intractable seminal vesiculitis. The present study summarizes the clinical outcomes following the use of transurethral seminal vesiculoscopy to diagnose and treat patients with intractable seminal vesiculitis.
Patients and methods

Patient population
This prospective observational study enrolled consecutive patients who had recurrent haematospermia with lower abdominal or perineal pain and discomfort between December 2007 and September 2012 in the Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China. None of the patients had a history of poorly controlled hypertension, abnormal liver function, coagulation abnormalities, or a history of trauma to or tumours in the urogenital tract. Urinalysis and prostatic fluid examinations prior to enrolment had been normal. Routine semen analysis had demonstrated normal semen volume (>2 ml) and red blood cells (RBC; rated from þ to þ þ þ þ [most serious haematospermia]), based on the quantity of RBCs present in the semen. Preoperative TRUS and MRI examinations had not revealed any congenital abnormalities or tumours in the urogenital tract. Before admission, patients had received standard regimens of systemic antibiotics and local physiotherapy for 3-6 months. However, the symptoms in the patients had been persistent or recurrent and the patients were therefore considered to have intractable seminal vesiculitis on study enrolment.
Approval for this study was granted by the Ethics Committee of Nanjing Medical University, Nanjing, Jiangsu Province, China and written informed consent was obtained from all study participants.
Transurethral seminal vesiculoscopy
Patients were placed under general anaesthesia in the dorsal lithotomy position. Transurethral seminal vesiculoscopy was performed using a Wolf F7 rigid ureteroscope (Henke-Sass, Wolf, Tuttlingen, Germany). First, the ureteroscope was inserted into the prostatic urethra for preliminary visualization of the verumontanum (the anatomical landmark near the entrance of the seminal vesicles). The bilateral ejaculatory duct openings were usually identified in the prostatic utricle. In some cases, the openings were located at a position lateral to the verumontanum. Under the guidance of a zebra guidewire (UROVISION, Achenmu¨hle, Germany) in the lumen, the ureteroscope was inserted into the ejaculatory ducts and seminal vesicles with the assistance of hand-controlled intermittent perfusion dilatation, using 0.90% (w/v) sodium chloride (normal saline) ( Figure  1A ). Then the bilateral ejaculatory ducts and seminal vesicles were observed on the endoscopic monitor. The seminal vesicles contained a honeycomb-like structure, congested walls and a milky, yellow or pink seminal vesicle fluid filled with flocculent turbidity and dark blood clots ( Figure 1B ). No congenital abnormalities or tumours were observed in the ejaculatory ducts and seminal vesicles. The seminal vesicles were washed repeatedly using normal saline through the endoscopic working channel until the seminal vesicle fluid became clear ( Figure 1C ). Then a 0.50% (w/v) levofloxacin solution was injected into the seminal vesicles. For those patients who had seminal vesicle stones, laser lithotripsy was performed using a SlimLine TM 200 micron Holmium Laser Fibre (Lumenis Õ , San Jose, CA, USA) ( Figure 1D ). Small and crushed stones were washed out or removed using stone forceps or a stone basket. Incomplete obstructions or stenosis of the ejaculatory ducts were incised and dilated by the Holmium Laser Fibre and endoscope. After the operation, a urethral Foley catheter (Bard, Murray Hill, NJ, USA) was retained in place overnight. All patients were required to refrain from ejaculation for !2 weeks and were followed up on a monthly basis for 6-12 months.
Results
A total of 114 patients were considered to have intractable seminal vesiculitis and were eligible for inclusion in the study. The mean AE SD age was 35.3 AE 5.8 years (range 22-54 years). The mean AE SD disease duration was 9.0 AE 2.7 months (range 5-18 months). Laser lithotripsy was performed for seminal vesicle stones in 12 patients.
Postoperative outcomes are shown in Table 1 . Of the 114 patients, 106 successfully underwent bilateral transurethral seminal vesiculoscopy. During the procedure, the ejaculatory duct openings were found to be covered with white membranous tissues in 39% of patients (41/106). Valve-like tissues existed in the ejaculatory duct openings of 4% of patients (four of 106). The mean operative time was 32 min (range 20-50 min). The mean length of hospitalization was 3 days. The mean duration of follow-up was 10 months. Six patients with postoperative painful ejaculation were treated successfully by the administration of standard regimens of oral antibiotics and a-blockers. Two cases of postoperative epididymitis were treated successfully with a 1-week standard course of antibiotics. There were no severe complications (such as retrograde ejaculation, rectal injury or urethral sphincter damage). In 94 of 106 (89%) patients, macroscopic haematospermia had disappeared 1 month after the operation; at this timepoint pain and discomfort had either disappeared or had been obviously relieved. No RBCs were found during postoperative microscopic semen analysis in 95% of these patients (89/94); in the remaining five patients, microscopic examination of the semen revealed RBCs (þ). In eight of the 94 patients in whom symptoms disappeared, haematospermia was recurrent during the follow-up period. Six patients still reported lower abdominal or perineal pain and discomfort.
Haematospermia and pain coexisted in two patients at follow-up.
Eight patients failed to receive bilateral transurethral seminal vesiculoscopy. The clinical outcomes of these eight patients are shown in Table 1 . In three cases, only a unilateral ejaculatory duct opening and a homolateral seminal vesicle were observed and treated. The bilateral ejaculatory duct openings could not be found using the ureteroscope in the remaining five cases. Surgical separation of the vas deferens through a small scrotal incision and further vasoseminal vesiculography through the puncture-exposed vas deferens demonstrated dysplasia of the ejaculatory duct openings. A 0.50% (w/v) levofloxacin solution was then injected into the vas deferens and seminal vesicles.
Discussion
Endoscopy was first applied by Shimada and Yoshida 8 to observe the internal structures of an excised seminal vesicle from a cystoprostatectomy specimen. This was followed by the first successful endoscopic examination of the seminal vesicles in a patient, in 1998. 9 Yang et al. 10 reported the first use of an ureteroscope being inserted through the ejaculatory duct openings to diagnose seminal vesicle disease. To date, few studies have focused on seminal vesiculoscopy in diagnosing and treating seminal vesiculitis. [11] [12] [13] [14] [15] The overall cure rate was reported as 78.6-97.6%, with the recurrence rate being <10%. [11] [12] [13] [14] [15] No severe complications were observed in these studies. [11] [12] [13] [14] [15] The present study investigated the use of transurethral seminal vesiculoscopy to analyse the cause of the seminal vesiculitis in 114 patients with an intractable form of the disease. To our knowledge, this is the largest study undertaken to date in this research area. The present study also reports the postoperative symptoms and complications following successful transurethral seminal vesiculoscopy. For those patients who were unable to undergo this novel procedure, details of their diagnoses and alternative treatments are provided.
Transurethral seminal vesiculoscopy can directly observe the urethra, prostate, ejaculatory ducts and seminal vesicles to identify some of the anatomical causes of seminal vesiculitis. In the present study, ejaculatory duct openings were covered with white membranous tissues or valve-like tissues. These abnormal anatomical factors could lead to poor drainage of the seminal vesicle fluid and consequently result in seminal vesiculitis. For the administration of therapy, transurethral seminal vesiculoscopy can directly wash the pathological seminal vesicles and inject therapeutic solutions into them. Coexistent stones, obstructions or stenoses can be treated simultaneously.
The results of the present study demonstrated that transurethral seminal vesiculoscopy was effective for the diagnosis and treatment of intractable seminal vesiculitis; its use was associated with a good safety profile. This simple procedure is minimally invasive as it is performed via the urogenital tract. No additional pieces of equipment or expertise are required. It is worth noting that not all of the patients with intractable seminal vesiculitis in this present study were cured by transurethral seminal vesiculoscopy. This was due to the numerous and complex causes of this disease. For example, eight patients were not suitable for transurethral seminal vesiculoscopy due to dysplasia of the ejaculatory duct openings. Future research will investigate the clinical characteristics of patients for whom transurethral seminal vesiculoscopy is not applicable. Of the 106 patients who underwent transurethral seminal vesiculoscopy, 12 had recurrent symptoms during the follow-up period. The postoperative recurrence of obstruction or stenosis might lead to recurrent symptoms. Understanding the causes of the poor outcomes in these 12 patients requires further research.
This present study had a number of limitations. The definition for intractable seminal vesiculitis remains unclear. The present study recruited patients according to the following criteria: (i) persistent, typical haematospermia and lower abdominal or perineal pain and discomfort; (ii) normal urinalysis and prostatic fluid examination; (iii) persistent or recurrent symptoms after systemic antibiotic therapy and local physiotherapy for 3-6 months. The study excluded patients with congenital abnormalities or tumours in the urogenital tract as determined by preoperative TRUS and MRI. Using different criteria for intractable seminal vesiculitis would lead to the enrolment of different patients, which might result in different clinical outcomes. It should be acknowledged that this present study only assessed short-term complications, which precludes the identification of longer term complications that might be theoretically related to the transurethral seminal vesiculoscopic process, such as seminal tract stenosis. Therefore, longer follow-up or the implementation of more diagnostic evaluation methods may be beneficial to determine the efficacy and safety of transurethral seminal vesiculoscopy. A previous small-scale study that investigated the antimicrobial susceptibility of chronic and recurrent seminal vesiculitis found that quinolones were the most sensitive drugs, 16 therefore a levofloxacin solution was used in the present study. Future research will focus on the infectious aetiology of intractable seminal vesiculitis in a larger number of patients, with a view to providing more targeted and individual drug choice.
In conclusion, transurethral seminal vesiculoscopy is a simple, minimally invasive procedure that is performed via the urogenital tract. Its use can avoid damage to the urethra, prostate and rectum, but the operating space is small. Therefore, careful and cautious operating procedures are essential to avoid bleeding and subsequent poor visibility. The positions of the ejaculatory duct openings are not anatomically fixed and sometimes membranous or valvelike tissues cover the openings, which can make transurethral seminal vesiculoscopy difficult to perform. Increasing the velocity of the normal saline perfusion and using a zebra guidewire for guidance are helpful for finding the openings. In some patients with anatomical abnormalities or dysplasia of the ejaculatory ducts, vas deferens puncture and injection of methylene blue, combined with transurethral endoscopy, can help with the observations of the ejaculatory duct openings. Vasoseminal vesiculography and drug injection are the alternative diagnostic and therapeutic methods if transurethral seminal vesiculoscopy is not possible. In addition, partial resection of the verumontanum tissues is beneficial in cases with severe distal obstruction of the ejaculatory duct, which was reported in our previous study. 17 Declaration of conflicting interest
